Payment overview · 2025
General Payments
$102.42
5 reported records · 3 companies
Healthcare provider profile · identity verified
Kimberly Baldock, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ASHLAND, KY · NPI 1144225657
Verified facts
What the public records show
CMS Open Payments records show Kimberly Baldock, MD received $102.42 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 45.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 264 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.29 | 45.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.11 | 34.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.02 | 20.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $102.42 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.29 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $35.11 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
264 | 67 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 733 | 185 |
| Gabapentin | Gabapentin | 556 | 91 |
| Pravastatin Sodium | Pravastatin Sodium | 446 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 437 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 401 | 109 |
| Famotidine | Famotidine | 401 | 112 |
| Omeprazole | Omeprazole | 394 | 104 |
| Potassium Chloride | Potassium Chloride | 340 | 99 |
| Duloxetine Hcl | Duloxetine Hcl | 314 | 70 |
| Furosemide | Furosemide | 309 | 98 |
| Losartan Potassium | Losartan Potassium | 291 | 79 |
| Lisinopril | Lisinopril | 281 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 274 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 268 | 80 |
| Synthroid | Levothyroxine Sodium | 264 | 67 |
| Tramadol Hcl | Tramadol Hcl | 255 | 44 |
| Montelukast Sodium | Montelukast Sodium | 235 | 64 |
| Metformin Hcl | Metformin Hcl | 217 | 57 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 215 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 50 |
| Ozempic | Semaglutide | 204 | 36 |
| Simvastatin | Simvastatin | 202 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 182 | 89 |
| Sertraline Hcl | Sertraline Hcl | 180 | 49 |
| Meloxicam | Meloxicam | 164 | 43 |
| Carvedilol | Carvedilol | 153 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 41 |
| Eliquis | Apixaban | 148 | 36 |
| Alendronate Sodium | Alendronate Sodium | 145 | 42 |
| Jardiance | Empagliflozin | 142 | 34 |
| Spironolactone | Spironolactone | 132 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 17 |
| Trulicity | Dulaglutide | 119 | 21 |
| Estradiol | Estradiol | 111 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 52 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 106 | 34 |
| Allopurinol | Allopurinol | 101 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 29 |
| Ezetimibe | Ezetimibe | 98 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 88 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 26 |
| Warfarin Sodium | Warfarin Sodium | 85 | 19 |
| Pregabalin | Pregabalin | 82 | 12 |
| Buspirone Hcl | Buspirone Hcl | 80 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 80 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 34 |
| Sucralfate | Sucralfate | 73 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 12 |
| Trazodone Hcl | Trazodone Hcl | 72 | 23 |
| Bupropion Xl | Bupropion Hcl | 69 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 21 |
| Cephalexin | Cephalexin | 66 | 47 |
| Atenolol | Atenolol | 65 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 64 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 34 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 63 | 25 |
| Methocarbamol | Methocarbamol | 60 | 13 |
| Klor-Con M20 | Potassium Chloride | 59 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 57 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 13 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 54 | 20 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 51 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 11 |
| Prednisone | Prednisone | 49 | 31 |
| Memantine Hcl | Memantine Hcl | 48 | 12 |
| Nifedipine Er | Nifedipine | 48 | 13 |
| Metformin Hcl Er | Metformin Hcl | 46 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 12 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Fluconazole | Fluconazole | 40 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Mirtazapine | Mirtazapine | 40 | 14 |
| Benazepril Hcl | Benazepril Hcl | 39 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | 11 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Levemir Flexpen | Insulin Detemir | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 24 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Lidocaine | Lidocaine | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Nystatin | Nystatin | 31 | 16 |
| Valsartan | Valsartan | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 13 |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 12 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | 11 |
| Wegovy | Semaglutide | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 15 |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 22 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Victoza 3-Pak | Liraglutide | 16 | suppressed |
| Acarbose | Acarbose | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | 13 |
| Digoxin | Digoxin | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Cytomel | Liothyronine Sodium | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Prevalite | Cholestyramine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Yuvafem | Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $102.42 · 5 records | ABBVIE INC. | Auvelity, OTEZLA, REPATHA, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error